Previous close | 3.2500 |
Open | 3.7000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 45.00 |
Expiry date | 2024-08-16 |
Day's range | 3.2500 - 3.7000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
PRINCETON, N.J., May 22, 2024--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries